Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Appendix 6: Cancer of the pancreas: MCBS eUpdate published online 20 June 2017 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).

× No keyword cloud information.

5 in total

1. A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer.

Authors: Koji Kikuchi; Akira Umemura; Hiroyuki Nitta; Hirokatsu Katagiri; Masao Nishiya; Noriyuki Uesugi; Tamotsu Sugai; Keisuke Imanari; Akira Sasaki
Journal: Surg Case Rep Date: 2022-10-07

2. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.

Authors: Kyoungmin Lee; Kyunghye Bang; Changhoon Yoo; Inhwan Hwang; Jae Ho Jeong; Heung-Moon Chang; Dongwook Oh; Tae Jun Song; Do Hyun Park; Sang Soo Lee; Sung Koo Lee; Myung-Hwan Kim; Jin-Hong Park; Kyu-Pyo Kim; Baek-Yeol Ryoo
Journal: Cancer Res Treat Date: 2019-07-09 Impact factor: 4.679

Review 3. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study.

Authors: Julien Taieb; Gerald W Prager; Davide Melisi; C Benedikt Westphalen; Nathalie D'Esquermes; Anabel Ferreras; Alfredo Carrato; Teresa Macarulla
Journal: ESMO Open Date: 2020-01

4. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.

Authors: Yung-Jue Bang; Chung-Pin Li; Kyung-Hun Lee; Chang-Fang Chiu; Joon Oh Park; Yan-Shen Shan; Jun Suk Kim; Jen-Shi Chen; Hyun-Jeong Shim; Kun-Ming Rau; Hye Jin Choi; Do-Youn Oh; Bruce Belanger; Li-Tzong Chen
Journal: Cancer Sci Date: 2019-12-20 Impact factor: 6.716

5. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.

Authors: Makoto Ueno; Shoji Nakamori; Kazuya Sugimori; Masashi Kanai; Masafumi Ikeda; Masato Ozaka; Masayuki Furukawa; Takuji Okusaka; Ken Kawabe; Junji Furuse; Yoshito Komatsu; Hiroshi Ishii; Atsushi Sato; Satoshi Shimizu; Priti Chugh; Rui Tang; Tatsuya Ioka
Journal: Cancer Med Date: 2020-10-25 Impact factor: 4.452

5 in total